- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02831920
CEUS Targeted Biopsies Compared to mpMRI Targeted and Systematic Biopsies for the Detection of Prostate Cancer
The current standard for Prostate Cancer (PCa) detection remains taking 10-12 systematic biopsies of the prostate. This approach leads to overdiagnosis of insignificant PCa on the one hand and underdiagnosis and undergrading of significant PCa on the other. multiparametric Magnetic Resonance Imaging (mpMRI) has seen an increasing uptake in the clinics for biopsy targeting, but the value in biopsy naive patients remains controversial. With Contrast Enhanced UltraSound (CEUS) cancer induced neovascularisation can be visualised with the potential to improve ultrasound imaging for prostate cancer detection and localisation significantly. The past years numerous studies have been performed with CEUS, all basing their results on subjective judgement of the investigator. To overcome these difficulties CEUS quantification techniques have been used with encouraging first results. These imaging techniques have been proposed to improve the yield of prostate biopsies and possibly replacing systematic biopsies.
In this trial mpMRI imaging and CEUS + quantification are performed before primary biopsy. Using a fusion device, targeted biopsies are taken from predefined MRI lesions and CEUS lesions, together with standard systematic biopsies in the same patients by separate blinded clinicians. The main outcome measure is the per-patient (significant) prostate cancer detection rate for each of the biopsy regimens.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hessel H. Wijkstra, Prof dr ir
- Phone Number: +31 20 5666379
- Email: h.wijkstra@amc.uva.nl
Study Locations
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Recruiting
- AMC University Hospital
-
Contact:
- H. Wijkstra, Prof.Dr.Ir.
- Phone Number: +31 20 5666379
- Email: h.wijkstra@amc.uva.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥ 18 years
- signed informed consent
- referred for mpMRI and primary biopsy
Exclusion Criteria:
- Documented acute prostatitis or urinary tract infections
- History of any clinically evidence of cardiac right-to-left shunts
- Receives treatment that includes dobutamine
- Severe pulmonary hypertension (pulmonary artery pressure >90 mmHg) or uncontrolled systemic hypertension or respiratory distress syndrome
- Has received a biopsy procedure within 30 days before admission into this study
- Has received a biopsy procedure at the Academic Medical Center within a year before admission into this study
- Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study
- Is incapable of understanding the language in which the information for the patient is given
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
every patient undergoes mpMRI and targeted biopsies, CEUS and targeted biopsies and systematic biopsies.
Every patient is therefore its own control.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
per-patient (significant) prostate cancer detection rate of mpMRI targeted biopsies
Time Frame: 2 weeks
|
2 weeks
|
per-patient (significant) prostate cancer detection rate of CEUS targeted biopsies
Time Frame: 2 weeks
|
2 weeks
|
per-patient (significant) prostate cancer detection rate of systematic biopsies
Time Frame: 2 weeks
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
complementarity of CEUS and mpMRI targeted biopsies in terms of per-patient (significant) cancer detection rate
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hessel H. Wijkstra, Prof dr ir, AMC University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- METC 2015_263
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
Clinical Trials on CEUS and targeted biopsies
-
Karolinska InstitutetCompleted
-
Lund University HospitalRecruiting
-
Shandong UniversityTongji Hospital; Wuhan Union Hospital, China; Zhejiang UniversityUnknownDiagnostic Yield of Gastric NeoplasiaChina
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Karolinska InstitutetCompleted
-
Ottawa Hospital Research InstituteRecruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University College London HospitalsCompleted
-
University College London HospitalsAdvanced Medical Diagnostics s.a.Unknown
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Recruiting